Trinity Biotech plc Sponsored ADR represents shares in Trinity Biotech plc, an Ireland-based commercial-stage biotechnology company headquartered in Bray. The company specializes in the development, acquisition, manufacture, and marketing of diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. Its offerings include test kits that detect infectious diseases such as HIV through products like Uni-Gold and TrinScreen, sexually transmitted diseases, autoimmune disorders, haemoglobin disorders, and support diabetes management via solutions like the Premier Hb9210 HbA1c system for monitoring blood glucose levels. Trinity Biotech also provides raw materials to the life sciences industry and has entered the wearable biosensor space for human diagnostics. Operating through segments in the Americas and Rest of World, it sells diagnostic systems, reagents, and instrumentation directly in key markets like the United States and Brazil, and via a global network of distributors and partners reaching over 100 countries. Manufacturing facilities span Ireland, the United States, and Brazil, enabling production of high-volume point-of-care tests and specialized laboratory products.
WebsiteIDA Business Park
Bray, A98 H5C8
Ireland
The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor
Tipranks Press Release.
- Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooling technologies for next-generation AI and modular data center infrastructure - Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 20331 DUBLIN and WILSONVILLE, Ore., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) today announced that Trinovium, a subsidiary focused on advanced liqui
Investors talking about TRIB also mention
What share of all stock conversation is about TRIB?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about TRIB that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 89.76% -0.4 | ||
| Bearish | — | — | — | 10.24% +0.4 |
Of the messages about TRIB that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | — | 42.55% | ||
| Analysts | — | — | — | 14.68% | ||
| Controversies | — | — | — | 0.43% | ||
| Earnings | — | — | — | 0.85% | ||
| Macro | — | — | — | 22.13% | ||
| Technical Analysis | — | — | — | 19.36% |
Of the messages about TRIB, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | — | 32.31% | ||
| Newcomers | — | — | — | 67.69% |